About this item:

255 Views | 496 Downloads

Author Notes:

Correspondence and requests for materials should be addressed to Y-s.Y. (email: yyoon5@emory)

S-J.L., C.P. and J.Y.L. designed and conducted the experiments and wrote the paper.

They contributed equally to this article.

S.K., P.J.K., W.K., Y.H.J. and E. L. conducted experiments and analyzed the data.

Y-s.Y. designed the study, analyzed the data, and wrote the paper.

We thank Drs. George Daley and In-Hyun Park for providing the human iPSC line BJ1 and technical advice.

The authors declare no competing financial interests.

Subjects:

Research Funding:

This work was supported in part by the NIH grant DP3DK094346, HL119291, by the NHLBI of NIH as a Program of Excellence in Nanotechnology (HHSN268201000043C), the National Science Foundation STC grant CBET-0939511 and ACTSI pilot grant (PHS grant UL1 RR025008 from the CTSA program, NIH, and National Center for Research Resources).

Keywords:

  • Science & Technology
  • Multidisciplinary Sciences
  • Science & Technology - Other Topics
  • MOUSE MODEL
  • DEFINED FACTORS
  • VASCULAR CELLS
  • DIFFERENTIATION
  • LYMPHANGIOGENESIS
  • EXPRESSION
  • INDUCTION
  • BLOOD
  • LINES
  • GENE
  • Pluripotent stem cells
  • Stem-cell differentiation

Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair

Tools:

Journal Title:

Scientific Reports

Volume:

Volume 5

Publisher:

Type of Work:

Article | Final Publisher PDF

Abstract:

Human pluripotent stem cells (hPSCs) have emerged as an important source for cell therapy. However, to date, no studies demonstrated generation of purified hPSC-derived lymphatic endothelial cells (LECs) and tested their therapeutic potential in disease models. Here we sought to differentiate hPSCs into the LEC lineage, purify them with LEC markers, and evaluate their therapeutic effects. We found that an OP9-assisted culture system reinforced by addition of VEGF-A, VEGF-C, and EGF most efficiently generated LECs, which were then isolated via FACS-sorting with LYVE-1 and PODOPLANIN. These hPSC-derived LYVE-1 + PODOPLANIN + cells showed a pure committed LEC phenotype, formed new lymphatic vessels, and expressed lymphangiogenic factors at high levels. These hPSC-derived LECs enhanced wound healing through lymphangiogenesis and lymphvasculogenesis. Here we report, for the first time, that LECs can be selectively isolated from differentiating hPSCs, and that these cells are potent for lymphatic vessel formation in vivo and wound healing. This system and the purified hPSC-derived LECs can serve as a new platform for studying LEC development as well as for cell therapy.

Copyright information:

© 2015, Macmillan Publishers Limited

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote